The Pharma Letter M&A roundup - August 2022

2 September 2022

mergers_acquisitions_2022_shutterstock_large

Big pharma dealmakers joined holidaymakers by taking a break in August - but a few pharmaceutical acquisitions did happen elsewhere in the industry.

The month's biggest deal by disclosed value came when Switzerland-headquartered eye-care company Alcon (SIX: ALC) acquired US ophthalmic drugs specialist Aerie Pharmaceuticals (Nasdaq: AERI).

Another sizeable buy was Catalent's (NYSE: CTLT) acquisition of Metrics Contract Services (Metrics), a specialty contract development and manufacturing organization previously owned by Australian drugmaker Mayne Pharma Group Limited (ASX: MYX), for $475 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK